These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A. J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862 [Abstract] [Full Text] [Related]
4. Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test. Shen Y, Gong J, He Y, Cheng G, Okunieff P, Li X. J Virol Methods; 2013 Feb; 187(2):288-93. PubMed ID: 23201290 [Abstract] [Full Text] [Related]
6. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ. J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244 [Abstract] [Full Text] [Related]
12. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening]. Wang JJ, Dong J, Deng ZX, Wang PF, Zhang XX, Du Y. Zhonghua Fu Chan Ke Za Zhi; 2019 May 25; 54(5):301-306. PubMed ID: 31154710 [Abstract] [Full Text] [Related]
13. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers. Basu P, Banerjee D, Mittal S, Dutta S, Ghosh I, Chowdhury N, Abraham P, Chandna P, Ratnam S. J Med Virol; 2016 Jul 25; 88(7):1271-8. PubMed ID: 26693677 [Abstract] [Full Text] [Related]
14. Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in Germany. Iftner T, Neis KJ, Castanon A, Landy R, Holz B, Woll-Herrmann A, Iftner A, Staebler A, Wallwiener D, Hann von Weyhern C, Neis F, Haedicke-Jarboui J, Martus P, Brucker S, Henes M, Sasieni P. J Clin Microbiol; 2019 Jan 25; 57(1):. PubMed ID: 30355760 [Abstract] [Full Text] [Related]
15. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany. Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, Staebler A, Henes M, Rall K, Haedicke J, von Weyhern CH, Clad A, Brucker S, Sasieni P. J Clin Microbiol; 2015 Aug 25; 53(8):2509-16. PubMed ID: 26019212 [Abstract] [Full Text] [Related]
17. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples. Liu TY, Xie R, Luo L, Reilly KH, He C, Lin YZ, Chen G, Zheng XW, Zhang LL, Wang HB. J Virol Methods; 2014 Feb 25; 196():120-5. PubMed ID: 24216236 [Abstract] [Full Text] [Related]